Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383Phase 2Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Aug 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of deulumateperone in generalized anxiety disorder (GAD) (3 arms), sponsored by Intra-Cellular Therapies. Primary endpoint: Hamilton Anxiety Rating Scale at 6 weeks. Started Aug 2024; status: recruiting.
02
Drugs
deulumateperone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06480383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480383.